Allogene Therapeutics
Janet Lee has extensive experience in the biopharmaceutical industry, particularly in process development for allogeneic CAR T therapies. Currently serving as Associate Director and Principal Scientist at Allogene Therapeutics since 2018, Janet has a strong background in designing and executing experiments using Design of Experiments (DOE) methodologies. Previous roles include positions at Pfizer and Cedars-Sinai, where efforts focused on optimizing large-scale production of allogeneic CAR T cells and investigating genetic susceptibility to ovarian cancer. Educational qualifications include a Master of Science in Biochemistry and Molecular Biology from the Keck School of Medicine of the University of Southern California and a Bachelor of Science in Chemistry from the University of California, Berkeley.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.